Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Amikacin nebulization

PreclinicalSmall molecule

CCliniques universitaires Saint-Luc- Université Catholique de Louvain

Amikacin nebulization is one of 2 small molecule programs targeting Nebulization. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

NebulizationCompleted

NebulizationPreclinical

Completed

Competition

Competitive Landscape

1 competitor in Nebulization

#DrugCompanyPhaseTrials

Amikacin nebulization

CCliniques universitaires Saint-Luc- Université Catholique de Louvain

Amikacine

CCliniques universitaires Saint-Luc- Université Catholique de Louvain

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Nebulization1 trial

Evaluation of the Timing of the Nebulization Related to the Physiotherapy Session

Completed·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·N/A·NCT02201082·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Amikacin nebulization. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Amikacin nebulization compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Amikacin nebulization. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cliniques universitaires Saint-Luc- Université Catholique de Louvain company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCliniques universitaires Saint-Luc- Université Catholique de Louvain

Related News